Antibody_edited.jpg

TRANSFORMING HEALTHCARE IN SOUTHEAST ASIA AND BEYOND

KGbio is developing innovative biologic therapy for high unmet medical need in largely underserved areas.

 

ABOUT US

Pioneering Biologic Drug Development in Southeast Asia

  • Kalbe Genexine Biologics (KGbio), established in 2016, is a joint venture between Kalbe Farma, the Southeast Asia's largest public pharmaceutical company, and Genexine, a clinical stage biotechnology company.

  • OUR VISION: To be the leader in biologic drug development in Southeast Asia.

  • OUR MISSION: To provide innovative biologic and immuno-oncology products, and better solutions in treating human diseases.

  • OUR BUSINESS: We are an innovative drug development company, focusing on 
    pre-clinical and clinical development, CMC process development, regulatory and quality compliance.

  • Leveraging Kalbe's manufacturing and commercial infrastructure and Genexine's expertise in biologic drug development, KGbio aims to provide high quality and affordable innovative biologics and immuno-oncology products to Southeast Asian countries and beyond.

 
Screen Shot 2020-01-28 at 6.51.23 PM.png

OUR PIPELINE

Rapidly Growing Pipeline with Two Products in Phase III Studies

EFEPOETIN ALFA

In-licensed from Genexine

Efepoetin alfa or GX-E4 is a novel long-acting erythropoietin-hybrid Fc fusion protein. It is being evaluated in a phase III study for treatment of anemia related to chronic kidney disease in Southeast Asian countries, Taiwan and Australia.

PD1 ANTIBODY

In-licensed from Henlius

HLX10 is a humanized anti-PD1 monoclonal antibody. It is being evaluated for treatment of multiple tumor indications as well as chronic hepatitis B infection. KGBio has taken licenses for squamous non-small-cell lung cancer and hepatocellular carcinoma indications in which global phase III studies are in progress or about to start. 

CD73 ANTIBODY

In-licensed from I-MAB Biopharma

TJD5 is a CD73-antagonistic antibody. CD73 is the rate-limiting enzyme that converts extracellular AMP to adenosine, a potent immunosuppressive molecule in the tumor micro-environment. TJD5 is being evaluated in a phase I study in combination with atezolizumab.

 
Test Tubes

MANAGEMENT TEAM

Our passion for creating meaningful change for underserved patients is what sets us apart. The KGbio team believes in the potential of our great idea, and we work tirelessly in order to bring you a better tomorrow. We are proud of every single member of staff.

 

SIE DJOHAN

CEO

  • Director of Kalbe

  • Pres. Commissioner of Sanghiang Perkasa, Innolab Sains International

  • President Director of Kalgen DNA

  • Director of Bifarma Adiluhung, Kalbio Global Medika and Innogene Kalbiotech

  • Director of Corporate Business Development, Management System & Regulatory Affairs at Kalbe

ADVISORY BOARD

 

YOUNG CHUL SUNG PH.D.

  • Founder and CEO of Genexine

  • Professor, Dept Life Sciences, POSTECH Institute

  • Ph.D, Univ. Minnesota

Lab Experiment

GET IN TOUCH

Kalbe building 3rd floor. Jl. Letjend Suprapto Kav 4, Jakarta 10510, Indonesia

(6221) 42873888

 

(6221) 42873888

  • Facebook
  • Twitter
  • LinkedIn

©2020 by kgbio.co.id. Proudly created with Wix.com